Featured Research

from universities, journals, and other organizations

National Jewish Researchers Show Intravenous Immunoglobulin Reduces Steroid Insensitivity, Hospitalizations Of People With Severe Asthma

Date:
March 19, 1999
Source:
National Jewish Medical And Research Center
Summary:
People with severe asthma who are "insensitive" to steroids need less of the medication, fewer "bursts" of it in emergencies and spend less time in the hospital when using intravenous immunoglobulin (IVIG) in conjunction with steroids, according to research published today in the Journal of Allergy and Clinical Immunology.

DENVER-People with severe asthma who are "insensitive" to steroids need less of the medication, fewer "bursts" of it in emergencies and spend less time in the hospital when using intravenous immunoglobulin (IVIG) in conjunction with steroids, according to research published today in the Journal of Allergy and Clinical Immunology.

Researchers found that during the 6-month study, patients had fewer hospitalizations for asthma attacks than in the 6 months prior to the study, even though they used less glucocorticoids, known generally as steroids.

IVIG also was as effective in people whose asthma can be treated with glucocorticoids, as it was in people whose asthma usually doesn't respond to glucocorticoids, or who are "steroid-insensitive." Researchers believe IVIG increases steroid sensitivity of the lungs to steroids, in part, by reducing lung inflammation. "We saw patients whose asthma does very poorly and who needed high doses of steroids to control the disease," said Erwin Gelfand, M.D., a pediatric immunology and asthma specialist and chair of the Department of Pediatrics at National Jewish Medical and Research Center.

While steroid-insensitive patients must take higher doses to achieve minimal control of their disease, they also may become dependent on the medication to breathe normally. Researchers found that by taking IVIG in conjunction with glucocorticoids, patients could use less glucocorticoids more efficiently.

Long-term use of glucocorticoids can stunt growth in children or cause osteoporosis, while IVIG has few side effects. "Compared to steroids, IVIG is not toxic at all," Dr. Gelfand said. "In addition, lowering the amount of steroids a patient takes reduces side effects and the patient's quality of life improves dramatically."

IVIG treatments cost several thousand dollars each month for people with severe asthma, but many health insurance companies cover the cost because, as this study shows, IVIG lowers emergency room and hospital use by patients with severe asthma. Glucocorticoids reduce inflammation in the lungs. IVIG is an antibody that is removed from the plasma portion of blood and is concentrated for use as a medication. IVIG can regulate the immune/inflammatory system and has been shown to reduce inflammation in the lungs.

National Jewish Medical and Research Center is ranked as the best hospital in the United States for respiratory diseases by U.S. News & World Report, 1998-1999.


Story Source:

The above story is based on materials provided by National Jewish Medical And Research Center. Note: Materials may be edited for content and length.


Cite This Page:

National Jewish Medical And Research Center. "National Jewish Researchers Show Intravenous Immunoglobulin Reduces Steroid Insensitivity, Hospitalizations Of People With Severe Asthma." ScienceDaily. ScienceDaily, 19 March 1999. <www.sciencedaily.com/releases/1999/03/990316130947.htm>.
National Jewish Medical And Research Center. (1999, March 19). National Jewish Researchers Show Intravenous Immunoglobulin Reduces Steroid Insensitivity, Hospitalizations Of People With Severe Asthma. ScienceDaily. Retrieved July 29, 2014 from www.sciencedaily.com/releases/1999/03/990316130947.htm
National Jewish Medical And Research Center. "National Jewish Researchers Show Intravenous Immunoglobulin Reduces Steroid Insensitivity, Hospitalizations Of People With Severe Asthma." ScienceDaily. www.sciencedaily.com/releases/1999/03/990316130947.htm (accessed July 29, 2014).

Share This




More Health & Medicine News

Tuesday, July 29, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Generics Eat Into Pfizer's Sales

Generics Eat Into Pfizer's Sales

Reuters - Business Video Online (July 29, 2014) Pfizer, the world's largest drug maker, cut full-year revenue forecasts because generics could cut into sales of its anti-arthritis drug, Celebrex. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com
Nigeria Ups Ebola Stakes on 1st Death

Nigeria Ups Ebola Stakes on 1st Death

Reuters - Business Video Online (July 29, 2014) Nigerian authorities have shut and quarantined a Lagos hospital where a Liberian man died of the Ebola virus, the first recorded case of the highly-infectious disease in Africa's most populous economy. David Pollard reports Video provided by Reuters
Powered by NewsLook.com
Running 5 Minutes A Day Might Add Years To Your Life

Running 5 Minutes A Day Might Add Years To Your Life

Newsy (July 29, 2014) According to a new study, just five minutes of running or jogging a day could add years to your life. Video provided by Newsy
Powered by NewsLook.com
Ebola Outbreak Poses Little Threat To U.S.: CDC

Ebola Outbreak Poses Little Threat To U.S.: CDC

Newsy (July 29, 2014) The Ebola outbreak in West Africa poses little threat to Americans, according to officials with the Centers for Disease Control and Prevention. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins